Virtual Symposium:
Targeted Protein Degradation & PROTAC
16 - 17 February 2021 | GMT (UTC+0)

Advances in Targeted Protein Degradation in target validation, therapeutics development and translation in the clinic.

The programme brings together world leaders from pharmaceutical and biotechnology companies as well as academic institutions to discuss the latest in Targeted Protein Degradation and PROTAC innovation

Download Agenda
Full details on the symposium, including the presentations, topic areas and confirmed speakers can be found in the conference brochure
Book Online

Full Registration is now open for Virtual Symposium: Targeted Protein Degradation & PROTAC. Please click the button below to register for this event.

LinkedIn Group

Our LinkedIn group aims to foster discussion and collaboration between experts working in pathology, biomarker development and translational research.

Headline Sponsor

Thought Leader

Business Developer

Programme

The Virtual Symposium: Targeted Protein Degradation & PROTAC includes...

Attendees representing global pharmaceutical organisations, leading biotech companies, internationally renowned academic and healthcare institutions discuss the latest in Targeted Protein Degradation and PROTAC innovation

  • Accelerate discovery & emerging strategies in targeted protein degradation and PROTAC
  • Reconfiguring how drug discovery projects can be approached within the context of Targeted Protein Degradation (TPD)
  • Effective use of mass spectrometry-based proteomics profiling as a discovery tool for understanding the mechanisms of action of drug candidates, including small molecule protein degraders
  • Addressing traditionally undruggable targets in areas of high patient need
  • Successfully degrade intracellular and extracellular targets, leverage the power of the ubiquitin- proteasome system & autophagy-mediated degradation
  • Benefit from the development of degraders from a medicinal chemistry perspective: application of structural biology and rational design strategies
  • Optimizing & Interrogating Protein Structures With Small Molecules, Molecular Glues And PROTAC
  • Gain insights on E3 Ligase Recruiter To Ubiquitinate And Mark Proteins Of Interest For Proteasomal Degradation
  • Optimize PK/PD properties of next generation protein degraders for applications in oncology and beyond

Agenda at a Glance

Day One: 16 February

  • Interrogating Protein Structures With Molecular Glues And Developing New Therapeutic Modalities
  • Developing New Therapeutic Modalities For Targeting The Protein Degradation Machinery
  • Monovalent Degraders/Molecular Glue Degraders
  • Design of Degraders and PROTAC In Cellular Development
  • Bifunction Small Molecules For Degrading Extracellular Proteins
  • Interrogating Protein Structures With Small Molecules, Molecular Glues And PROTACS
  • Protein Degradation Workshop – Development of Degraders From A Medicinal Chemistry Perspective
  • E3 Ligase Recruiter To Ubiquitinate And Mark Proteins Of Interest For Proteasomal Degradation
  • Reimagining Druggability using Chemoproteomic Platforms


Day Two: 17 February

  • Panel Discussion: Protein Degradation – Strategies Beyond The Proof Of Concept Molecules
  • PROTAC- Receptor Kinase Targets & PKPD
  • Protein Degradation For Developing New Targets in Oncology
  • The Impact Of Mass Spectrometry-Based Proteomics For Targeted Protein Degradation
  • Enabling DNA Encoded Libraries as a High Content Discovery Tool for Protein Degradation Molecules
  • Optical Control of Protein Degradation
  • Delivering Clinical Candidate Drugs Using Degraders
  • TRK Degraders for Oncology – New Modality For The Treatment Of Cancer
  • Protein Degradation Seminar Workshop -Translation to the Clinic
  • Optimize PK/PD properties of next generation protein degraders for applications in oncology and beyond
  • Translation Of Protein Degradation Probes Into Safe, Effective Therapeutics

Confirmed Speakers

The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future

Georg-Winter

Georg Winter

CeMM Research Centre for Molecular Medicine

Xavir

Xavier Jacq

Almac Discovery Ltd

Ben-Cross

Benedict Cross

PhoreMost

Michael-Plewe

Michael Plewe

Cullgen

James-Schiemer

James Schiemer

Pfizer

matthew_disney

Matthew Disney

Scripps Research

Dan Nomura

Daniel Nomura

University of California

Ian Churcher

Ian Churcher

Amphista Therapeutics Limited

Giulia-Caron

Giulia Caron

University of Torino

choudhary, amit

Amit Choudhary

Harvard Medical School

Dirk Trauner

Dirk Trauner

NYU

Bin-Yang

Bin Yang

Kymera Therapeutics

Event Features​

Networking and knowledge Sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of Series features and make the most of participation in a range of virtual, remote experiences. 

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Live Q&As

Interact with fellow attendees and speakers during the live Q&As at the end of each presentation

Digital Networking Opportunities

Connect directly with other registrants of event around the world

Syngene

Headline Sponsor

Syngene is an integrated research, development and manufacturing organisation providing scientific services – from early discovery to commercial supply. We offer services in a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies. Our culture of scientific innovation is driven by the expertise of our highly qualified team of 5,000 employees and supported by state-of-the-art infrastructure and market- leading technology.

We offer clients a customised end-to-end solution to fulfil their R&D and manufacturing requirements. This is underpinned by a well-established safety framework, track record of quality and compliance, robust supply chain and access to skilled scientists. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations due to our shared interest in the science and commitment to project delivery.

We recognise that trust is built incrementally project-by-project and we pride ourselves on the many deep, long-term client relationships that underpin our business and demonstrate the value of the work we do.

Biotheryx

Thought Leader Sponsor

Wuxi AppTec

Headline Sponsor